Our Solutions

A significant portion of our efforts at Novion Technologies (NOVION) are directed towards the development of solutions that target wound infections and medical device-related infections. Our innovative family of silver-thiolate antiseptics (GlutAgaSept(TM)) can be tailored to exhibit varying degrees of antimicrobial efficacy and corresponding cellular toxicity with benefits that can include protease inhibition, color stability, water solubility, antioxidant capacity, biofilm penetration, and resistance to inactivation by chloride. NOVION’s GlutAgaSept(TM) family of compounds are far superior to “silver” as it is known in today’s medical device market.

In a related effort at Iasis Molecular Sciences (IASIS), we have developed a family of Multicomponent Additives that impart antimicrobial character to the materials into which they are formulated. Our studies are directed at combating healthcare acquired infections (HAIs) by addressing the looming threat of pathogenic organisms on medical devices, coated surfaces to include painted surfaces, flooring, and other hard and soft surfaces known to harbor and transmit pathogens in the hospital and public environments. Target medical devices and components include urinary (Foley) catheters, central venous catheters, suprapubic catheters, ureteric stents, endotracheal tubes, catheter dressings, catheter hubs, connectors, butterfly suture flanges, septa, solvent-based and RTV adhesives, and decorative paints, epoxy flooring coatings, and industrial performance coatings to include marine antifouling coatings, and powder coatings.

A list of our projects and solutions in development are shown below.

 

Healthcare Problem Iasis Molecular Sciences Solution Successes & Traction
Burns Antimicrobial dressings, ointments & gels formulated to include MAPIs with the ability to inhibit proteases and deliver antiseptic and/or antibiotic (ions), a reformulated silver sulfadiazine (a WHO essential medicine) improved by the inclusion of a simple (GRAS) adjuvant that provides greater overall efficacy without impeding wound closure, and several silver compounds with the promise of being effective against biofilm, possessing significantly better therapeutic indices than current (commercial) antiseptic options, and the ability to reduce oxidative stress resulting from inflammation. Each of these targets possesses excellent potential for a variety of pharmaceutical and/or medical device applications including wound dressings, topical formulations, and medical device coatings. Preclinical proof of concept via phase 1 NIH SBIR grant award (NIGMS, complete) and CDMRP (DoD) award (on-going), patents pending.
Periodontal Disease An antimicrobial-antiprotease irrigation therapy using controlled release MAPIs address the bacterial burden and excessive proteolysis known to contribute to tissue and tooth loss with disease progression. Proof of concept phase 1 SBIR NIH grant award (NIDCR), complete. Patents pending.
Surgical Wounds Adhesive surgical site dressings formulated with antimicrobial MAPIs and MAPAs. Proof of concept via phase 1 SBIR grant award (NIDDK), Patents pending. Preclinical proof of concept via phase 1 NIH SBIR grant awarded (NIGMS), September 2012.
Preventing Device-Related & Nosocomial Infections Medical material formulations with proprietary additives (MAPAs) that address pathogenic organisms. MAPA derivatives bind and release oligodynamic metals and organic antimicrobial compounds. Proof of concept (formulation & bacteriology) complete, Development on-going, Patents pending.
Eliminating Environmental Pathogens and Biofouling Organisms with Self-Disinfecting Surfaces Coatings and bulk polymeric materials can be formulated to include proprietary additives (MAPAs) to yield surfaces that kill pathogenic organisms and/or minimize biofilms that can lead to infection and/or biofouling. Our MAPA derivatives bind and slowly release oligodynamic metal ions and ionic organic antimicrobial compounds. Development and testing (formulation & bacteriology) of aqueous decorative paint formulations, epoxy and acrylic surfaces are on-going, Patents pending.
Chronic Wounds Wound dressings, ointments, creams, and gels formulated with MAPIs including a protease inhibiting antiseptic ionomer as well as novel silver-based antimicrobial agents (including a reformulated silver sulfadiazine), all of which have demonstrated greatly improved selectivity for bacteria (i.e. greatly reduced eukaryotic cell toxicity) and have proven superbly efficacious in preclinical testing. Presently Novion has three antiseptic candidate compounds and one antibiotic candidate in development. These compounds are anticipated to provide a robust product portfolio of topical creams and gels, medical devices such as wound dressings, and coatings for short- and long-term medical devices for the prevention of infection. Proof of concept via phase 1 SBIR grant award (NIA) (formulation & bacteriology) complete. Development on-going. Patents pending. Preclinical proof of concept via phase 1 NIH SBIR grant awarded (NIAID), September 2012.